Tumor lysis syndrome induced by tebentafusp

Area of Science:

• Oncology
• Immunotherapy
• Pharmacology

Background:

• Tebentafusp is a novel bispecific protein targeting gp100 and CD3, approved for HLA-A*02:01-positive metastatic uveal melanoma.
• Its administration requires dose escalation and inpatient monitoring due to the risk of cytokine-release syndrome.
• Adverse event profiles of new therapies are crucial for safe clinical application.

Purpose of the Study:

• To report a case of tumor lysis syndrome following a single dose of tebentafusp.
• To highlight the importance of recognizing and managing rare but serious adverse events associated with tebentafusp therapy.
• To increase healthcare professional awareness of tebentafusp's side effect profile.

Main Methods:

• Case report of a patient treated with tebentafusp for metastatic uveal melanoma.
• Monitoring for and management of adverse events, specifically tumor lysis syndrome.
• Therapeutic intervention including rasburicase for tumor lysis syndrome.

Main Results:

• A patient developed tumor lysis syndrome after a single tebentafusp infusion.
• Prompt and adequate therapy, including rasburicase, led to the patient's full recovery.
• Cytokine-release syndrome is a known side effect, but tumor lysis syndrome is a less common, severe event.

Conclusions:

• Tebentafusp, while effective, carries risks of serious adverse events like tumor lysis syndrome.
• Awareness and prompt management are critical for patient safety in tebentafusp therapy.
• Healthcare professionals must be vigilant for the full spectrum of tebentafusp-related side effects.